Elisa Andrini

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 8

Top Topics

Transcription Factor

Neuroendocrine Tumors

Top Venues

Current oncology (Toronto, Ont.)

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti, Davide Campana
Prospective Evaluation of MGMT -Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current oncology (Toronto, Ont.) 30 (2) (2023)
Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti, Davide Campana
Prospective Evaluation of MGMT -Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current oncology (Toronto, Ont.) 30 (2) (2023)
Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti, Davide Campana
Prospective Evaluation of MGMT -Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current oncology (Toronto, Ont.) 30 (2) (2023)
Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti, Davide Campana
Prospective Evaluation of MGMT -Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current oncology (Toronto, Ont.) 30 (2) (2023)
Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti, Davide Campana
Prospective Evaluation of MGMT -Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current oncology (Toronto, Ont.) 30 (2) (2023)
Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti, Davide Campana
Prospective Evaluation of MGMT -Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current oncology (Toronto, Ont.) 30 (2) (2023)
Elisa Andrini, Alessandro Di Federico, Monia Sisi, Matteo Rosellini, Arianna Palladini, Giuseppe Lamberti, Andrea De Giglio, Francesco Gelsomino
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. Immunotherapy 14 (16) (2022)
Elisa Andrini, Giuseppe Lamberti, Francesca Mazzoni, Ferdinando Riccardi, Andrea Bonetti, Alessandro Follador, Fabrizio Artioli, Carlo Genova, Fausto Barbieri, Antonio Frassoldati, Matteo Brighenti, Ida Colantonio, Giulia Pasello, Corrado Ficorella, Saverio Cinieri, Marcello Tiseo, Francesco Gelsomino, Michele Tognetto, Karim Rihawi, Andrea Ardizzoni
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale. Future oncology (London, England) 18 (7) (2022)